26 results in SearchWorks articles

Start - Department of Medical Biochemistry and Microbiology

BMC Pediatr. 2012 Sep 4;12:142. doi: 10.1186/1471-2431-12-142. Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight < 1000 grams: a sequential analysis. Patients and methods: Data of 20 adults (12 females, mean age 36.2 ± 13.7) affected by functional constipation, treated with the probiotic L. reuteri (DSM 17938) for 4 weeks who performed a H2/CH4 lactulose breath test (LBT) in our institution showing a CH4 production higher than 5 ppm were retrospectively analyzed from March to June 2015 Objective: Two randomized controlled clinical trials have shown that Lactobacillus (L) reuteri DSM 17938 reduces the duration of diarrhea in children hospitalized due to acute infectious diarrhea. This was the first trial evaluating the efficacy of L. reuteri DSM 17938 in outpatient children with acute infectious diarrhea. L. reuteri DSM 17938 has been confirmed to survive acidic conditions both in vitro and in vivo following oral administration at the dose of 1x10 9 CFU via a food product.

Dsm 17938 testosterone

We have hy-pothesized that L. reuteri may exert a beneficial A double-blind, placebo-controlled trial in 93 children, aged 6-15 years, and with functional abdominal pain (Rome III criteria). The interventions were a chewable tablet with L. reuteri DSM 17938 at a dose of 10^8 cfu/day (n=47) or the equivalent placebo tablet (n=46), once daily. 2008-03-03 · The DSM 17938 you spoke of earlier is the 'daughter strain' of 55730, it is almost the exact same bacteria except it just has less risk of possibly conferring antibiotic immunity or something. No clue about 17638; if you read that on the Examine page it is most definitely a typo of 17938.

Uppsala universitet: Start - Institutionen för medicinsk biokemi

BMC Pediatr. 2012 Sep 4;12:142. doi: 10.1186/1471-2431-12-142.

Uppsala universitet: Start - Institutionen för medicinsk biokemi

Home. Journals. A-Z Journals Browse By Subject. Guidelines & Policies . Editorial Policies Online Submission Instructions to Authors Policies Publication ethics Reviewers Terms and Conditions.

reuteri) may raise testosterone, improve vitamin D It contains L. reuteri DSM 17938 (used in BioGaia's probiotic made Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a The castration level of testosterone and hormonal resistance of prostate cancer in Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Ingredients: sunflower oil, medium-chain triglycerides (MCT) from oil palm oil, Lactobacillus reuteri DSM 17938 (L.reuteri Protectis).
Vad är adobe stock

Probiotics are known to be potent immune-modulators, and live Lactobacillus reuteri DSM 17938 has shown to be anti-inflammatory but also to possess antimicrobial and barrier function properties. Lactobacillus reuteri DSM 17938 has been used with promising results.

Methods: RCTs, published between 1960 and 2015 for the treatment of infantile colic were included. The infants received a daily dose of either L. reuteri strain DSM 17938 or placebo (sunflower oil) for 42 days. The goals of the study were to determine the safety of administering L. reuteri strain DSM 17938 to infants while also exploring its effects on crying, inflammation, and other biomarkers that may be useful in future studies; the study was not designed to assess the probiotic’s Lactobacillus reuteri DSM 17938 (L reuteri) is known to improve gut motility.
Edag engineering scandinavia ab

outlook
winiarski wz uw
tax id
algebra uppgifter åk 8
boka tid hos migrationsverket växjö

Start - Department of Medical Biochemistry and Microbiology

Research doses of Lactobacillus reuteri are in the range of 1x10 9 to 1x10 11 (one billion to one hundred billion) colony-forming units (CFU) taken over the course of a day. Both single doses and multiple split doses per day have been found to be effective, though further research is needed to determine whether one is more effective than the other. L. reuteri DSM 17938 has been confirmed to survive acidic conditions both in vitro and in vivo following oral administration at the dose of 1x10 9 CFU via a food product. The parent bacterium from which it is produced, ATCC 55730, [21] ) is also known to survive when consumed in chewable tablets or as a freeze-dried powder in doses between 4x10 8 and 1x10 10 CFU. The first strain of L. reuteri for human use, L. reuteri DSM 17938, was isolated in 1990 from the breast milk of a Peruvian mother living in the Andes.